Hagiwara, Akifumi
Schlossman, Jacob
Shabani, Soroush
Raymond, Catalina
Tatekawa, Hiroyuki
Abrey, Lauren E.
Garcia, Josep
Chinot, Olivier
Saran, Frank
Nishikawa, Ryo
Henriksson, Roger
Mason, Warren P.
Wick, Wolfgang
Cloughesy, Timothy F.
Ellingson, Benjamin M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation
https://doi.org/10.1007/s11060-022-04088-3
Funding for this research was provided by:
UCLA SPORE in Brain Cancer (NIH/NCI 1P50CA211015-01A1, NIH/NCI 1P50CA211015-01A1)
American Cancer Society (ACS) Research Scholar Grant (RSG-15-003-01-CCE)
University of California Research Coordinating Committee
UCLA Jonsson Comprehensive Cancer Center Seed Grant
NIH/NCI (1R21CA223757-01)
Article History
Received: 1 June 2022
Accepted: 2 July 2022
First Online: 17 July 2022
Declarations
:
: BME is on advisory board of Hoffman La-Roche, Siemens, Nativis, Medicenna, MedQIA, Bristol Meyers Squibb, Imaging Endpoints, and Agios. BME is a paid consultant of Nativis, MedQIA, Siemens, Hoffman La-Roche, Imaging Endpoints, Medicenna, and Agios. BME has grant funding by Hoffman La-Roche, Siemens, Agios, and Janssen. The other authors declare no competing interests.
: The study protocol was approved by the applicable independent ethics committee and institutional review board at each participating institution. All patients provided written informed consent to participate in the AVAglio trial (NCT00943826) and the clinical trial adhered to the principles of the Declaration of Helsinki and the Guidelines for Good Clinical Practice.